Presentations

      An Assessment Strategy for Modified-Risk Tobacco Products (MRTP)

      Poussin, C.

      Conference date
      Feb 3, 2017
      Conference name
      Portuguese Society of Pharmacology
      Link to more information
      Link to more information
      Topic
      Summary

      With dual expertise in biochemistry and computational sciences, Dr Carine Poussin leads various R&D projects in systems toxicology. These projects include risk assessment of new products, development of in vitro cardiovascular mechanistic assay portfolio and pre-clinical to clinical translational research. She also drives projects in the fields of computational data analysis and elaboration of crowd-sourced computational challenges for methods and data verification in systems biology and toxicology (sbvimprover.com).

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.